NCT05196360 (PD-L1) is a Phase 1 clinical trial of MAX-10181 in Solid Tumor, sponsored by Maxinovel Pty., Ltd..

Who is sponsoring NCT05196360?

NCT05196360 is sponsored by Maxinovel Pty., Ltd..

What drugs are being tested in NCT05196360?

Interventions in NCT05196360: MAX-10181.

What condition does NCT05196360 study?

NCT05196360 studies Solid Tumor.

Is NCT05196360 still recruiting?

NCT05196360 is currently status unknown. Last updated 19 January 2022.

Last reviewed 2022-01-19 · How we verify

NCT05196360: PD-L1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MAX-10181 in Patients With Advanced Solid Tumor

Status unknown Phase 1 Last updated 19 January 2022

What this trial tests

Phase 1 trial testing MAX-10181 in Solid Tumor in 80 participants. Status unknown.

Timeline

11 August 2021

Primary endpoint
1 January 2023

1 May 2023

Quick facts

Lead sponsor	Maxinovel Pty., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	11 August 2021
Primary completion	1 January 2023
Estimated completion	1 May 2023
Sites	1 location across China

Drugs / interventions tested

MAX-10181 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Maxinovel Pty., Ltd. — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecule-based immunomodulators for cancer therapy.
Wu Y, Yang Z, Cheng K, Bi H, et al · · 2022 · cited 71× · PMID 36562003 · DOI 10.1016/j.apsb.2022.11.007
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.
Xiao L, Zhang L, Guo C, Xin Q, et al · · 2024 · cited 37× · PMID 38923737 · DOI 10.1002/cac2.12579
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy.
Zhang Y, Wu J, Zhao C, Zhang S, et al · · 2023 · cited 21× · PMID 37056391 · DOI 10.7150/jca.81899
Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy.
Slota A, Golebiowska-Mendroch K, Kocik-Krol J, Musielak B, et al · · 2025 · cited 4× · PMID 40666457 · DOI 10.1021/acsmedchemlett.5c00245
Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy.
Yin JY, Liu HM, Li SL, Ji XQ, et al · · 2026 · PMID 42094596 · DOI 10.7150/thno.130935

Verify or expand the search:

Other trials of MAX-10181

Trials testing the same drug.

NCT04122339 — MAX-10181 Given Orally to Patients With Advanced Solid Tumor · Phase 1 · unknown

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Maxinovel Pty., Ltd. trials

Trials by the same sponsor.

NCT05425602 — A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors · Phase 1, PHASE2 · unknown
NCT05369286 — A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors · Phase 1 · unknown
NCT05196711 — A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects · Phase 1 · unknown
NCT05130021 — A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer · Phase 2 · unknown
NCT05061147 — A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-4027 · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05196360 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maxinovel Pty., Ltd.
Last refreshed: 19 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05196360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing